Ascendis Pharma to Exchange ADSs 1:1 and List Ordinary Shares April 20
Ascendis Pharma will exchange all outstanding ADSs for ordinary shares at a 1:1 ratio and commence direct listing on Nasdaq Global Select Market under ticker ASND on April 20, 2026. The simplified structure with new CUSIP K08588103 and ISIN DK0060606333 aims to enhance institutional ownership and trading liquidity.
1. Direct Listing Mechanics
On April 20, 2026 Ascendis Pharma will transition from American Depositary Shares to a direct listing of ordinary shares, exchanging each ADS for one ordinary share under its existing ticker ASND on the Nasdaq Global Select Market.
2. New Identifiers and Trading Start
The newly listed ordinary shares will trade under CUSIP K08588103 and ISIN DK0060606333, replacing the current ADS identifiers, and will begin trading at the market open on the listing date.
3. Benefits and Market Impact
The shift to a direct listing and simplified capital structure is intended to broaden global investment access, support potential inclusion in key equity indexes, and boost institutional ownership and overall trading liquidity.